The potential impact of human visceral leishmaniasis vaccines on population incidence by Rutte, E.A. (Epke) le et al.
RESEARCH ARTICLE
The potential impact of human visceral
leishmaniasis vaccines on population
incidence
Epke A. Le RutteID
1,2,3*, Luc E. CoffengID1, Stefano MalvoltiID4, Paul M. Kaye5, Sake J. de
VlasID
1
1 Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The
Netherlands, 2 Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
Basel, Switzerland, 3 University of Basel, Basel, Switzerland, 4 MM Global Health Consulting, Zurich,




Human visceral leishmaniasis (VL) vaccines are currently under development and there is a
need to understand their potential impact on population wide VL incidence. We implement
four characteristics from different human VL vaccine candidates into two published VL trans-
mission model variants to estimate the potential impact of these vaccine characteristics on
population-wide anthroponotic VL incidence on the Indian subcontinent (ISC). The vaccines
that are simulated in this study 1) reduce the infectiousness of infected individuals towards
sand flies, 2) reduce risk of developing symptoms after infection, 3) reduce the risk of devel-
oping post-kala-azar dermal leishmaniasis (PKDL), or 4) lead to the development of tran-
sient immunity. We also compare and combine a vaccine strategy with current interventions
to identify their potential role in elimination of VL as a public health problem. We show that
the first two simulated vaccine characteristics can greatly reduce VL incidence. For these
vaccines, an approximate 60% vaccine efficacy would lead to achieving the ISC elimination
target (<1 VL case per 10,000 population per year) within 10 years’ time in a moderately
endemic setting when vaccinating 100% of the population. Vaccinating VL cases to prevent
the development of PKDL is a promising tool to sustain the low incidence elimination target
after regular interventions are halted. Vaccines triggering the development of transient
immunity protecting against infection lead to the biggest reduction in VL incidence, but
booster doses are required to achieve perduring impact. Even though vaccines are not yet
available for implementation, their development should be pursued as their potential impact
on transmission can be substantial, both in decreasing incidence at the population level as
well as in sustaining the ISC elimination target when other interventions are halted.
PLOS NEGLECTED TROPICAL DISEASES







Citation: Le Rutte EA, Coffeng LE, Malvolti S, Kaye
PM, de Vlas SJ (2020) The potential impact of
human visceral leishmaniasis vaccines on
population incidence. PLoS Negl Trop Dis 14(7):
e0008468. https://doi.org/10.1371/journal.
pntd.0008468
Editor: Angamuthu Selvapandiyan, JH-Institute of
Molecular Medicine, INDIA
Received: January 14, 2020
Accepted: June 10, 2020
Published: July 2, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pntd.0008468
Copyright: © 2020 Le Rutte et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript.
Funding: EALR, LEC, and SJDV gratefully
acknowledge funding of the NTD Modelling
Author summary
Vaccines for human visceral leishmaniasis (VL) are currently under development. In this
study, we simulate VL transmission dynamics using mathematical models to explore the
potential impact of vaccines on population-wide incidence. We show that some vaccines
have high potential to reduce VL incidence, namely those that reduce the infectiousness of
infected individuals to sand flies and those that reduce the chance of developing symp-
toms once infected. The effect of vaccines that lead to protection from infection is poten-
tially the greatest, but depending on the duration of immunity, individuals would require
booster doses to guarantee lifelong impact. Vaccines that prevent the development of
post-kala-azar dermal leishmaniasis are a promising tool to sustain low VL incidence and
prevent recrudescence of infection when regular interventions are halted. Our results
strongly support the continued development of VL vaccines, as their potential impact on
population incidence can be substantial.
Introduction
Visceral leishmaniasis (VL), also known as kala-azar, is a vector-borne neglected tropical dis-
ease. Infection occurs after successful transmission of the Leishmania protozoa through the
bite of an infected female sand fly [1]. Most infected humans remain asymptomatic, and only a
small proportion of about 1–10% develop clinical symptoms, resulting in death when left
untreated [2,3]. Between 5% and 20% of treated VL cases develop a long-lasting skin condition
known as post-kala-azar dermal leishmaniasis (PKDL). Recent studies have identified that
individuals with PKDL are equally infectious towards sand flies as VL cases, making them an
important reservoir of infection [4,5]. However, the contribution of asymptomatic individuals
to transmission has not yet been defined [4,6]. After infection, a period of immunity follows,
of which the duration remains debated.
Currently around 33,000–66,000 individuals develop symptomatic VL each year, mainly on
the Indian subcontinent (ISC), Eastern Africa, the Mediterranean region, and Brazil, affecting
the poorest of the poor [7,8]. The World Health Organization (WHO) and affected countries
target for ‘elimination of VL as a public health problem by 2020’ on the ISC, where VL is con-
sidered to be solely anthroponotic. This target is defined as maintaining less than 1 VL case
per 10,000 individuals per year at district level in Nepal, at subdistrict/block level in India, and
at upazila level in Bangladesh [9]. In the rest of the world (e.g Africa, Europe, Brazil), where
VL can also be zoonotic with the main reservoir of infection in dogs, the target is 100% detec-
tion and treatment of symptomatic cases [10]. Current strategies consist of diagnosis and treat-
ment of VL cases, and vector control.
Vaccines already play an important role in the control of canine leishmaniasis, at the indi-
vidual level they reduce the development of symptoms, reduce the parasite load in the blood,
and reduce the risk of death [11–13]. These vaccines have also proven to be effective at the
population level by reducing Leishmania transmission, resulting in lower incidence in both
dogs and humans [14,15]. The development of human VL vaccines has been on-going for
decades and there are different vaccine candidates currently in trial, but none are yet available
for implementation [16,17]. The promising results from experimental human VL vaccine tri-
als, and by the practice of “leishmanization”, in which a healthy individual is artificially
exposed to tissue scrapings derived from a cutaneous leishmaniasis patient, leading to disease
prevention [6,16,18–20], provide strong evidence for the scientific feasibility of an effective
vaccine against human VL. Should an effective vaccine become available, it has been estimated
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to be cost-effective when used at large scale and in addition to ongoing diagnosis and treat-
ment, without even accounting for its impact on transmission [19].
Mathematical transmission models are useful tools to gain insight into the effect of current
and future interventions on VL incidence and the underlying transmission dynamics. Previous
modelling studies that focused on VL transmission on the ISC presented two model variants;
one in which only VL and PKDL cases contribute to transmission, and another in which also
asymptomatic individuals contribute to transmission (~1% relative to VL cases). The models
estimated that in most situations on the ISC, the target is likely to be met with current strate-
gies but in high endemic settings and at a lower geographical scale, additional efforts are
required. They also highlighted the risk of recrudescence of infection after achieving the low
incidence target, when halting interventions. This is mainly due to individuals with PKDL
and/or asymptomatic infection. Therefore, the studies emphasized the need for further
research on the potential impact of preventive VL and PKDL strategies as a tool in reaching
and sustaining VL elimination as a public health problem on the ISC [5,21,22]. Other studies
stressed that 100% detection and treatment of cases in the rest of the world remains challeng-
ing and that prevention could be much more effective than case detection and treatment [23].
In this study, we implement multiple characteristics of potential human VL vaccines using
the two variants of a deterministic VL transmission model [21] to estimate the potential impact
of these vaccine characteristics on VL incidence and transmission dynamics during and after
the achievement of the current elimination target. The vaccines that are simulated in this study
1) reduce the infectiousness of infected individuals towards the sand fly, 2) reduce the risk of
developing symptoms after infection, 3) reduce the risk of development of PKDL, or 4) lead to
the development of transient immunity to infection [24–26]. We also compare and combine
vaccine characteristics with current interventions to identify which vaccines could be most
impactful in fighting this neglected tropical disease.
Methods
Overview of VL vaccine candidates and characteristics
Currently there are various VL vaccine candidates under study [27]: LEISH-F3+GLA-SE
[28,29], and ChAd63-KH (ISRCTN07766359) [30] are currently in clinical development;
Ad5-A2/rA2 Prime / Boost [31], genetically modified live attenuated whole parasites
[25,26,32], and a LmCen-/- vaccine [33] are being developed for the clinic [34].
These vaccines have different physical and immunological properties, and could be used in
either prophylactic or therapeutic settings, but their impact following infected sand fly bite in
humans has yet to be evaluated. Table 1 summarizes different potential vaccine outcome mea-
sures (herein called characteristics) that were selected for simulation in this study. Vaccine
characteristic 1 is separated into 1a) asymptomatic individuals and 1b) all infected individuals,
because it is suggested that only individuals with asymptomatic infection may be affected by
the vaccine and that once an individual develops symptoms there are no differences in
Table 1. Human VL vaccine characteristics.
Number Vaccine characteristic
1a Reduced infectivity of asymptomatic individuals
1b Reduced infectivity of all infected individuals
2 Reduced risk of developing symptoms
3 Reduced risk of developing PKDL
4 Development of transient immunity protecting against infection
https://doi.org/10.1371/journal.pntd.0008468.t001
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infectiveness (1a). However, since this is not yet well established, we also include the option
where all infected individuals become less infective, as a result of the vaccine (1b).
Transmission models and simulation of existing interventions
Fig 1 illustrates the basic structure of the VL transmission model, which is a deterministic age-
structured model. There are two model variants, that only differ based on assumptions about
where the main reservoir of infection lies; namely, solely in symptomatic individuals (VL and
PKDL), or mainly in asymptomatic individuals [21,35,36]. The models were parameterized
with age-structured data on approximately 21,000 individuals included in the KalaNet bednet
trial in India and Nepal [37] and have undergone geographical cross-validation against data
on>5000 VL cases from 8 endemic districts in Bihar collected by CARE India [38] (see [36]
Fig 1. Schematic presentation of the model variant in which asymptomatic individuals contribute to transmission, with numbers related to different types of
vaccine characteristics that are implemented in the models. In the alternative model variant, asymptomatic individuals are assumed not to be infectious towards to
sand fly, with infection pressure only coming from symptomatic individuals with VL (with and without treatment) and PKDL. Once a susceptible individual is infected
by an infectious sand fly, they become early asymptomatic for an average duration of about 200 days, which is followed by the late asymptomatic stage (average duration
of 69 days). The average infectivity of both asymptomatic stages together is 0 in the model in which they do not contribute and ~1.5% relative to VL in the model in
which they contribute to transmission. 1.4% of late asymptomatic individuals develops VL, and without active case detection, the duration between onset of symptoms
and start of treatment lasts on average 40 days, followed by 1-day treatment 1 and potentially 28-day treatment 2 or death if left untreated. The average duration of the
putatively recovered stage is 21 months and 5% of these individuals develop PKDL which lasts 5 years on average. The infectivity of PKDL is 90%, relative to VL. The
rest recovers to the early recovered stage (average duration of 74 days), followed by the late recovered stage (average duration of 2 years), which can be interpreted as the
duration of immunity. The numbers in the red boxes relate to the numbers in the first column of Table 1 and represent the following vaccine characteristics; 1a) early
and late asymptomatic individuals become half as infectious, 1b) all infection states become half as infectious, 2) vaccinated individuals are 50% less likely to develop
symptoms, 3) vaccinated individuals are 50% less likely to develop PKDL, and 4) vaccinated individuals develop transient immunity against infection.
https://doi.org/10.1371/journal.pntd.0008468.g001
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for full model code and descriptions, and sensitivity analyses). Recent outcomes from xenodi-
agnosis studies have been incorporated, indicating that those with PKDL are on average nearly
as infectious as those with VL (0.9:1.0) [4,5].
Interventions of which the effects have previously been modelled are vector control through
indoor-residual spraying of insecticide (IRS) and active case detection (ACD). The guidelines,
as developed by WHO, recommend a 5-year attack phase (intense IRS and ACD) followed by
5 years of consolidation phase (IRS and intense ACD). In our models, IRS leads to a decrease
in sand fly density and ACD shortens the duration of the symptomatic untreated stage.
Implementation and simulation of four vaccine characteristics
Vaccine characteristic 1 is simulated by a reduction in infectiousness of infectious states
towards the sand fly. For vaccine characteristics 2 and 3, the respective flow towards clinical
VL and PKDL is reduced. With vaccine characteristic 4, we selected 100% development of
transient immunity after having received the vaccine and experimented with vaccinating 100%
and 50% of the population. The duration of immunity after vaccination is assumed to be to 2
years, which is similar to the assumed duration of immunity after natural infection in our
model of which sensitivity analyses are presented in previous work [36].
For the simulations of vaccine characteristics, we assume that they apply to everyone
involved, i.e. all ages and sexes. No specific target populations are simulated, besides for vac-
cine characteristic 3, which is only administered to those that have developed VL. For vaccine
characteristics 1–3, we assume an arbitrary 50% reduction of the infectiousness as well as a
50% reduction of the proportions of individuals that develop VL and PKDL, all in combination
with a 100% vaccination coverage. We also calculate the percentage of vaccine effectiveness
required to achieve the VL elimination target incidence of 1/10,000/year within 10 years of
starting the intervention, which could aid in defining a vaccine target product profile (TPP).
We assume that the vaccine characteristics are in place constantly from the start of the inter-
vention, except for vaccine characteristic 4, where we experiment with simulating a single vac-
cination round and repeated yearly vaccination rounds. For all four vaccine characteristics, we
separately simulate and compare their impact on VL incidence over time, even though it is
likely that one vaccine will possess multiple characteristics. The cumulative effects of some vac-
cine characteristics are simulated indirectly, as reducing the development of VL will lead to a
decrease in the overall development of PKDL. Previous work has shown that when current
existing interventions have led to the 1/10,000/year target, there are many susceptible individu-
als and the infection pressure comes mainly from PKDL cases (when assuming the infection
pressure originates from symptomatic individuals only) [21]. To address this, we also combine
vaccine characteristic 3, vaccination of VL cases to prevent the development of PKDL, with the
current interventions recommended by WHO.
Results
The impact of each of the four vaccine characteristics on VL incidence is illustrated in Fig 2. A
vaccine that reduces infectivity of asymptomatic individuals by 50% (1a) leads to achievement
of the target of less than 1 VL case per 10,000 population per year in about 11 years. When all
infected individuals have a reduced infectiousness of 50% (1b), the decline is steeper, achieving
elimination in around 4 years if asymptomatics are the main reservoir of infection and 11
years when infection is only coming from those with VL and PKDL. Halving the chance of
developing symptoms (2) also has a considerable impact on transmission, especially if only
symptomatic individuals are infective after which elimination takes about 10 years. However,
if most infection pressure arises from asymptomatic individuals, the impact of halving the
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development of symptoms will lead to achieving the elimination target only after about 19
years, when used as a stand-alone tool. A 50% reduction in the development of PKDL (3), after
which not 5% (default) but only 2.5% of past VL cases develop PKDL, has the smallest impact
on transmission. As expected with this characteristic, the relatively larger impact is seen when
only those with VL and PKDL contribute to transmission, and thus when PKDL plays a more
prominent role in the transmission dynamics. Of all vaccine characteristics, the development
of immunity that protects against infection (as seen in late recovered cases) of the population
causes the most rapid decrease in incidence (4), since the pool of susceptible individuals is
completely removed at once (with the assumption of 100% coverage as used in the model). We
Fig 2. The impact of different vaccine characteristics on VL incidence using model variants with and without asymptomatics contributing to
transmission in a setting with a pre-control endemicity of 5/10,000/year. Vaccine characteristics are in place continuously from year 0 onwards, unless
for vaccine characteristic 4, which is administered once (1 x 100%), or yearly for five years in a row (5 x 50%). The different vaccine characteristics that are
also explained in Table 1 and illustrated in Fig 1, are; 1a) early and late asymptomatic individuals become half as infectious, 1b) all infection states become
half as infectious, 2) vaccinated individuals are 50% less likely to develop symptoms, 3) vaccinated individuals are 50% less likely to develop PKDL, and 4)
vaccinated individuals become immediately immune. The black dashed line represents the WHO elimination target of 1/10,000/year. The oscillations in VL
incidence are a result of seasonality in the sand fly density.
https://doi.org/10.1371/journal.pntd.0008468.g002
PLOS NEGLECTED TROPICAL DISEASES The potential impact of human visceral leishmaniasis vaccines on population incidence
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008468 July 2, 2020 6 / 13
additionally explored the effect of vaccinating half the population and repeating this yearly for
5 years in a row (5 x 50%), showing that regular vaccinations are required to sustain the impact
and move towards the low incidence elimination target.
The minimum vaccine effect required for each vaccine characteristic to achieve the VL
elimination target incidence of 1/10,000/year within 10 years of starting the intervention is
presented in Table 2. The vaccine characteristics that impact the development of VL and
PKDL (2 and 3) obviously have a bigger impact in the model in which only VL and PKDL con-
tribute to transmission.
Vaccine characteristic 3, after which vaccinated individuals are less likely to develop PKDL,
displayed the least impact when used as a stand-alone tool. Fig 3 shows the impact on VL inci-
dence of a decrease in the development of PKDL of 50% and 100%, combined with the current
interventions for a setting with a pre-control endemicity level of 5/10,000/year. The red line
represents the default scenario in which the current interventions (active case detection and
vector control) are in place during the WHO attack phase (year 0–5) and the WHO consolida-
tion phase (year 5–10), without the presence of a vaccine. Further details on the impact of cur-
rent interventions on VL incidence on the ISC as predicted by these models can be found in Le
Rutte et al., 2018 [21]. After halting all interventions at year 10, the situation will slowly return
to the pre-control equilibrium of 5/10,000/year, because of the remaining VL incidence in year
10 in all scenarios. In the two scenarios with the PKDL vaccine (green and blue lines) a new,
much lower, equilibrium will be reached after regular interventions are halted. For the vaccine
with a 50% efficacy (50% decrease in PKDL development of vaccinated VL cases) the target of
1/10,000/year will be reached as simulated by the model in which only VL and PKDL contrib-
ute to transmission. When assuming an effect of 100% protection from developing PKDL, this
model suggests that using only vaccine 3 could keep the incidence below 1/10,000/year, after
all regular interventions have brought incidence down and are halted. However, in settings
with a higher pre-control endemicity of 10/10,000/year, only the vaccine with 100% protection
against development of PKDL will lead to the elimination target of VL after 15–20 years
depending on the start year of the PKDL vaccine.
Discussion
In this study, we present for the first time the potential impact of VL vaccines on transmission
dynamics and population incidence on the Indian subcontinent (ISC). This impact looks very
promising. We found that all simulated vaccine characteristics show potential in reducing pop-
ulation VL incidence, particularly those that reduce the infected individual’s infectiousness or
reduce the chance of developing symptoms once infected. For these vaccines, an approximate
Table 2. Minimum required effect of the vaccine characteristics to reach a VL elimination target incidence of 1/10,000/year within 10 years’ time after starting the
intervention, when vaccinating 100% of the population in a setting with a 5/10,000/year pre-control incidence.
Model variant
Vaccine characteristic Only VL and PKDL contribute to
transmission
Asymptomatics are main contributors to
transmission
1a) required reduction in infectivity of asymptomatic individuals N/A 35%
1b) required reduction in infectivity of all infected individuals 60% 37%
2) required reduction in the development of symptoms 56% 68%
3) required amount of time to reach the elimination target when preventing the
development of PKDL completely
11 years >20 years
4) required minimum number of rounds when vaccinating 50% of the susceptible
individuals yearly with 100% vaccine efficacy
14 rounds 5 rounds
https://doi.org/10.1371/journal.pntd.0008468.t002
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60% vaccine efficacy would lead to achieving the ISC elimination target (<1 VL case per
10,000 population per year) within 10 years’ time in a moderately endemic setting, assuming
that the entire population is vaccinated and only VL and PKDL cases contribute to transmis-
sion. For the model variant in which asymptomatics are the main contributors to transmission,
much lower vaccine efficacies of around 37% would be required when reducing the infectious-
ness; however, for the required reduction in the development of symptoms, a vaccine efficacy
of nearly 70% was estimated. The vaccine that leads to immunity akin to that of late recovered
cases shows the highest impact, but individuals would require regular booster vaccines to
achieve and sustain the low incidence elimination target. Vaccinating VL cases to prevent the
development of PKDL shows to be a promising tool to sustain the elimination target once
reached, and prevent recrudescence of infection when regular interventions are halted. Those
Fig 3. Strategies of combining vaccine effect 3 with the WHO attack and consolidation phase for a setting with a pre-control endemicity level of 5/10,000/year.
Top panels: vaccine effect with 100% protection against the development of PKDL, bottom panels: vaccine effect with 50% protection against the development of
PKDL. The default strategy is visualized with the red line (top and bottom row identical), in which 5 years of attack phase are followed by 5 years of consolidation phase,
after which interventions are halted in year 10. For the green line, the PKDL vaccine is introduced during the consolidation phase (year 5), which continues after the
consolidation phase has ended at year 10. For the blue line, the PKDL vaccine is already introduced at the start of the attack phase (year 0), continues during the
consolidation phase and is continued when regular interventions are halted in year 10. Left figures show the simulations for the model variant where solely symptomatic
individuals contribute to transmission, whereas for the right figures asymptomatic individuals constitute the main reservoir of infection. The black dashed line
represents the WHO VL incidence target of 1/10,000/year. The oscillations in VL incidence are a result of seasonality in the sand fly density.
https://doi.org/10.1371/journal.pntd.0008468.g003
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findings are of great importance in providing a factual base to the ongoing effort aimed at
establishing a TPP for a VL vaccine.
A limitation to our study is the fact that we simulated vaccine characteristics rather simplis-
tically by instantaneously altering the transition rates and applying this simultaneously to all
individuals in the population. Ideally, vaccinated individuals should move to different, addi-
tional, compartments in the model, where they experience a different history of infection. In
such a model, vaccinated and unvaccinated individuals would be living beside each other, both
influencing the transmission dynamics differently, although the outcomes would likely only
differ quantitatively with ours. Another limitation of our study is that we only present the
results for a setting with a pre-control endemicity of 5 VL cases per 10,000 population per
year, which we considered representative for endemic situations where vaccines would be
most useful. In settings with a lower pre-control endemicity the elimination target would be
achieved earlier; in settings with a higher pre-control endemicity, the vaccine characteristics
would require a higher efficacy to achieve the same effect on VL incidence in the same amount
of time.
We further decided to simulate the vaccine characteristics separately, while in reality most
vaccines are expected to possess multiple characteristics. For example lowering the parasite
load will likely lead to both decreased infectiousness as well as reduced development of symp-
toms, as is also seen in canine VL vaccines [12,13]. However, by combining them it would be
less clear to what extent different characteristics would drive the total impact of a vaccine. For
the vaccine that causes vaccinated individuals to develop transient immunity against infection,
it is important to note that the impact on VL incidence, as well as the required number of
booster vaccines, highly depends on the duration of acquired immunity, which was assumed
to be two years on average in our models similar to what we used in previous work [36]. The
longer the duration of acquired immunity, the bigger the impact on VL incidence and the
lower the frequency of required booster vaccines. We also assume that for all vaccine charac-
teristics the efficacy is 50%. Even though this is a generalization and in reality it is likely differ-
ent for each characteristic, this approach allows us to compare the impact of the different
vaccine characteristics. In this study we simulate transmission between humans and sand flies,
which is currently considered to reflect the transmission dynamics of VL on the ISC. However,
would a considerable contribution to transmission come from an animal reservoir, vertical
transmission as seen in dogs, and/or the presence of those with HIV-VL co-infection, the
potential impact of vaccines could increase [13,39–41].
A typical aspect of the deterministic model that we use is that all durations of states are expo-
nentially distributed, which often does not reflect the actual distributions of durations as found
in nature. The slow recrudescence of infection between year 10 and 20 is another phenomenon
of the deterministic model, where prevalences can never become completely zero, but in reality
the disease will either die out or come back, and if it comes back, most likely it will progress
somewhat faster. Around the elimination target when numbers of infected cases become very
low, the role of chance increases and a stochastic transmission model would be required to ana-
lyse the risks of recrudescence or the chance of achieving (local) elimination of transmission.
We acknowledge that some of the assumptions chosen for the simulation are not fully
reflective of the reality of implemented immunization programs. Firstly, our choice of 100%
coverage certainly is an overestimation of what can be realistically achieved. For example, cov-
erage for the 1st dose of measles-containing vaccines was on average 73% in the AFRO region,
and the human papilloma virus vaccination had an average coverage of 88% when pooling
regions and income levels [42,43]. However, this assumption allowed us to evaluate the maxi-
mum impact and to do such an evaluation independently from the constraints of delivery
strategy. Also, having chosen another coverage level would not alter our outcomes when
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comparing the impact of the different characteristics. With a lower coverage, the durations
until elimination as a public health problem would be longer and the minimum required effi-
cacies would be higher. Secondly, and in particular at the start of vaccination programs, a
catch up campaign is usually implemented to quickly reduce the susceptible population, focus-
ing on the population that is at highest risk (i.e. for leishmaniasis, children and young adults or
migrant workers [44]). Such programmatic design considerations are not considered in the
current model and will need to be investigated with more complex individual-based transmis-
sion models. Lastly, 5-year protection is most likely going to be the minimum requirement to
allow for a widespread roll-out in routine immunization. Shorter durations requiring a very
frequent administration of booster doses might prove programmatically and financially unsus-
tainable. Nevertheless, from an impact assessment standpoint the results generated with the
more conservative assumptions of the current model have clear significance for understanding
the relative importance of different vaccine characteristics.
Vaccines have proven to be vital tools in the control and prevention of diseases [45,46].
This study reveals that a VL vaccine strategy could also prove an important tool in the fight
against this neglected tropical disease. We focussed on the anthroponotic transmission dynam-
ics of VL on the Indian subcontinent, but also in the rest of the world VL vaccines are likely to
surpass their impact at the patient level by reducing the infection pressure, positively impact-
ing the estimated 6 million people at risk of VL globally [47].
In conclusion, even though VL vaccines are not yet available for implementation, our
results strongly support their continued development, given the potentially substantive impact
on transmission, decreasing incidence at the population level, and sustaining the low incidence
elimination target on the ISC when other interventions are relaxed. More details of the impact
of different vaccines characteristics on the history of infection are awaited to further our
understanding and modelling of the impact of VL vaccines on VL transmission dynamics and
disease incidence.
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